Ingalls & Snyder LLC raised its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 3.1% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 198,263 shares of the biopharmaceutical company’s stock after purchasing an additional 5,910 shares during the period. Ingalls & Snyder LLC’s holdings in Bristol-Myers Squibb were worth $11,047,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in BMY. Waldron LP acquired a new position in Bristol-Myers Squibb during the 1st quarter valued at about $475,000. Mycio Wealth Partners LLC boosted its stake in Bristol-Myers Squibb by 18.5% during the 1st quarter. Mycio Wealth Partners LLC now owns 7,841 shares of the biopharmaceutical company’s stock valued at $426,000 after purchasing an additional 1,226 shares during the last quarter. Dubuque Bank & Trust Co. boosted its stake in Bristol-Myers Squibb by 8.2% during the 1st quarter. Dubuque Bank & Trust Co. now owns 17,289 shares of the biopharmaceutical company’s stock valued at $940,000 after purchasing an additional 1,307 shares during the last quarter. Delta Asset Management LLC TN boosted its stake in Bristol-Myers Squibb by 2.4% during the 1st quarter. Delta Asset Management LLC TN now owns 67,779 shares of the biopharmaceutical company’s stock valued at $3,686,000 after purchasing an additional 1,587 shares during the last quarter. Finally, Duncker Streett & Co. Inc. boosted its stake in Bristol-Myers Squibb by 8.9% during the 1st quarter. Duncker Streett & Co. Inc. now owns 60,769 shares of the biopharmaceutical company’s stock valued at $3,305,000 after purchasing an additional 4,972 shares during the last quarter. Institutional investors and hedge funds own 68.87% of the company’s stock.

A number of equities analysts have issued reports on BMY shares. Cowen and Company reiterated a “hold” rating and set a $65.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, September 19th. Jefferies Group LLC lifted their price target on Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, September 11th. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price target for the company. in a research note on Thursday, September 28th. UBS AG reiterated a “buy” rating and set a $72.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday. Finally, Hilliard Lyons downgraded Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price target for the company. in a research note on Tuesday, September 12th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. Bristol-Myers Squibb has an average rating of “Hold” and an average price target of $62.66.

In related news, Director Theodore R. Samuels II bought 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the acquisition, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now owns 46,297 shares in the company, valued at approximately $2,777,820. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at 64.15 on Tuesday. The company has a 50 day moving average of $61.78 and a 200-day moving average of $56.72. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $65.03. The company has a market cap of $105.20 billion, a PE ratio of 23.43 and a beta of 1.19.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter last year, the company posted $0.69 earnings per share. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. Equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 2.43%. The ex-dividend date is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/10/10/bristol-myers-squibb-company-bmy-shares-bought-by-ingalls-snyder-llc.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.